Rocio Herrero-Vanrell

Prof. Rocio Herrero-Vanrell

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Journal of Controlled Release
Verified
Journal Article
Closed access
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
ARA.C. Rincón
A.C. Rincón
MAM. Alonso
M. Alonso
VRV. Reboto
V. Reboto
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
JRJose Carlos Rodriguez-Cabello
Jose Carlos Rodriguez-Cabello

1 October 2001 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
MRMiguel F Refojo
Miguel F Refojo

Verified
Journal Article
Open access
PDF file
MLMarc Labetoulle
Marc Labetoulle
JCJose Manuel Benitze del Castillo
Jose Manuel Benitze del Castillo
SBStefano Barabino
Stefano Barabino
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
PDPhilippe Daull
Philippe Daull
MRMaurizio Rolando
Maurizio Rolando
Dry eye disease (DED) is the most common ocular surface disease, characterized by insufficient production and/or instability of the tear film. Tear substitutes are usually the first line of treatment for patients with DED. Despite the large variety of tear substitutes available on the market, few studies have been performed to compare their performance. There is a need to better understand the specific mechanical and pharmacological roles of each ingredient composing the different formulations. In this review, we describe the main categories of ingredients composing tear substitutes (e.g., viscosity-enhancing agents, electrolytes, osmo-protectants, antioxidants, lipids, surfactants and preservatives) as well as their effects on the ocular surface, and we provide insight into how certain components of tear substitutes may promote corneal wound healing, and/or counteract inflammation. Based on these considerations, we propose an approach to select the most appropriate tear substitute formulations according to the predominant etiological causes of DED.

1 September 2014 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
IBIrene Bravo-Osuna
Irene Bravo-Osuna
VAVanessa Andrés-Guerrero
Vanessa Andrés-Guerrero
MVMarta Vicario-De-La-Torre
Marta Vicario-De-La-Torre
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez

22 January 2021 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
JLJosé López-Cano
José López-Cano
MGMiriam Ana González-Cela-Casamayor
Miriam Ana González-Cela-Casamayor
VAVanessa Andrés-Guerrero
Vanessa Andrés-Guerrero
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
The development of ophthalmic formulations able to deliver hydrophilic and hydrophobic drugs to the inner structures of the eye and restore the preocular tear film has been a leading topic of discu...

1 November 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
PCPatricia Checa-Casalengua
Patricia Checa-Casalengua
CJCaihui Jiang
Caihui Jiang
IBIrene Bravo-Osuna
Irene Bravo-Osuna
BTBudd Tucker
Budd Tucker
IMIrene Teresa Molina-Martínez
Irene Teresa Molina-Martínez
RHRocio Herrero-Vanrell
Rocio Herrero-Vanrell